Amyris (AMRS) Stock Price, News & Analysis

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRS, but not buy additional shares or sell existing shares.
View AMRS analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12 month price targets for Amyris' shares. Their AMRS share price targets range from $0.65 to $1.50. On average, they expect the company's stock price to reach $1.10 in the next twelve months.
View analysts price targets for AMRS or view top-rated stocks among Wall Street analysts.

Amyris, Inc. (NASDAQ:AMRS) released its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. The biotechnology company had revenue of $47.90 million for the quarter, compared to the consensus estimate of $64.21 million. The firm's revenue for the quarter was up 39.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.41) earnings per share.

ETFs with the largest weight of Amyris (NASDAQ:AMRS) stock in their portfolio include AXS Cannabis ETF (THCX).VegTech Plant-based Innovation & Climate ETF (EATV).

Amyris's stock reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

84 employees have rated Amyris Chief Executive Officer John Melo on Glassdoor.com. John Melo has an approval rating of 54% among the company's employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Amyris to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia Oyj (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).